|
1
|
JCS Joint Working Group; Japanese Society
for Oral Health; Japanese Society of Oral and Maxillofacial
Surgeons; Japanese Society of Public Health; Japanese Respiratory
Society; Japan Society of Obstetrics and Gynecology; Japanese
Circulation Society; Japan Pediatric Society; Japanese College of
Cardiology; Japan Lung Cancer Society. Guidelines for Smoking
Cessation (JCS 2010) - digest version. Circ J. 76:1024–1043. 2012.
View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sobue T, Yamamoto S, Hara M, Sasazuki S,
Sasaki S and Tsugane S; JPHC Study Group; Japanese Public Health
Center. Cigarette smoking and subsequent risk of lung cancer by
histologic type in middle-aged Japanese men and women: the JPH
study. Int J Cancer. 99:245–251. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Powell HA, Iyen-Omofoman B, Baldwin DR,
Hubbard RB and Tata LJ: Chronic obstructive pulmonary disease and
risk of lung cancer: The importance of smoking and timing of
diagnosis. J Thorac Oncol. 8:6–11. 2013. View Article : Google Scholar
|
|
7
|
Kovalchik SA, Tammemagi M, Berg CD,
Caporaso NE, Riley TL, Korch M, Silvestri GA, Chaturvedi AK and
Katki HA: Targeting of low-dose CT screening according to the risk
of lung-cancer death. N Engl J Med. 369:245–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Torre GC: SCC antigen in malignant and
nonmalignant squamous lesions. Tumour Biol. 19:517–526. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pujol JL, Grenier J, Daurès JP, Daver A,
Pujol H and Michel FB: Serum fragment of cytokeratin subunit 19
measured by CYFRA 21-1 immunoradiometric assay as a marker of lung
cancer. Cancer Res. 53:61–66. 1993.PubMed/NCBI
|
|
10
|
Tirumalai RS, Chan KC, Prieto DA, Issaq
HJ, Conrads TP and Veenstra TD: Characterization of the low
molecular weight human serum proteome. Mol Cell Proteomics.
2:1096–1103. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okano T, Kondo T, Kakisaka T, Fujii K,
Yamada M, Kato H, Nishimura T, Gemma A, Kudoh S and Hirohashi S:
Plasma proteomics of lung cancer by a linkage of multi-dimensional
liquid chromatography and two-dimensional difference gel
electrophoresis. Proteomics. 6:3938–3948. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Latterich M, Abramovitz M and
Leyland-Jones B: Proteomics: New technologies and clinical
applications. Eur J Cancer. 44:2737–2741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seike M, Kondo T, Fujii K, Okano T, Yamada
T, Matsuno Y, Gemma A, Kudoh S and Hirohashi S: Proteomic
signatures for histological types of lung cancer. Proteomics.
5:2939–2948. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Seike M, Kondo T, Fujii K, Yamada T, Gemma
A, Kudoh S and Hirohashi S: Proteomic signature of human cancer
cells. Proteomics. 4:2776–2788. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seike M, Kondo T, Mori Y, Gemma A, Kudoh
S, Sakamoto M, Yamada T and Hirohashi S: Proteomic analysis of
intestinal epithelial cells expressing stabilized beta-catenin.
Cancer Res. 63:4641–4647. 2003.PubMed/NCBI
|
|
16
|
Okano T, Kondo T, Fujii K, Nishimura T,
Takano T, Ohe Y, Tsuta K, Matsuno Y, Gemma A, Kato H, et al:
Proteomic signature corresponding to the response to gefitinib
(Iressa, ZD1839), an epidermal growth factor receptor tyrosine
kinase inhibitor in lung adenocarcinoma. Clin Cancer Res.
13:799–805. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al; West Japan Oncology Group. Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar
|
|
19
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kelly E, Greene CM, Carroll TP, McElvaney
NG and O'Neill SJ: Alpha-1 antitrypsin deficiency. Respir Med.
104:763–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagareda T, Takeda M, Kojima K, Tanaka A,
Terada N, Yamasaki T, Nagareda T, Ueno H and Kotoh K: Alpha-1
anti-chymotrypsin is increased in human alveolar macrophages by
phorbol myristate acetate or lipopolysaccharide and released from
these activated macrophages by glucocorticoid. J Pathol.
165:319–323. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Poller W, Faber JP, Weidinger S, Tief K,
Scholz S, Fischer M, Olek K, Kirchgesser M and Heidtmann HH: A
leucine-to-proline substitution causes a defective alpha
1-antichymotrypsin allele associated with familial obstructive lung
disease. Genomics. 17:740–743. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ishii T, Matsuse T, Teramoto S, Matsui H,
Hosoi T, Fukuchi Y and Ouchi Y: Association between
alpha-1-antichymotrypsin polymorphism and susceptibility to chronic
obstructive pulmonary disease. Eur J Clin Invest. 30:543–548. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Turner GA: Haptoglobin. A potential
reporter molecule for glycosylation changes in disease. Adv Exp Med
Biol. 376:231–238. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dowling P, O'Driscoll L, Meleady P, Henry
M, Roy S, Ballot J, Moriarty M, Crown J and Clynes M: 2-D
difference gel electrophoresis of the lung squamous cell carcinoma
versus normal sera demonstrates consistent alterations in the
levels of ten specific proteins. Electrophoresis. 28:4302–4310.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bharti A, Ma PC, Maulik G, Singh R, Khan
E, Skarin AT and Salgia R: Haptoglobin alpha-subunit and hepatocyte
growth factor can potentially serve as serum tumor biomarkers in
small cell lung cancer. Anticancer Res. 24:1031–1038.
2004.PubMed/NCBI
|
|
27
|
Hoagland LF IV, Campa MJ, Gottlin EB,
Herndon JE II and Patz EF Jr: Haptoglobin and posttranslational
glycan-modified derivatives as serum biomarkers for the diagnosis
of nonsmall cell lung cancer. Cancer. 110:2260–2268. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takeda Y, Shinzaki S, Okudo K, Moriwaki K,
Murata K and Miyoshi E: Fucosylated haptoglobin is a novel type of
cancer biomarker linked to the prognosis after an peration in
colorectal cancer. Cancer. 15;118:3036–3043. 2012. View Article : Google Scholar
|
|
29
|
Wang B, He YJ, Tian YX, Yang RN, Zhu YR
and Qiu H: Clinical utility of haptoglobin in combination with CEA,
NSE and CYFRA21-1 for diagnosis of lung cancer. Asian Pac J Cancer
Prev. 15:9611–9614. 2014. View Article : Google Scholar : PubMed/NCBI
|
